CD44 and ovarian carcinoma: Cisplatin-encapsulating maleimide-polyethylene glycol-poly(d,l-lactic-co-glycolide) (mal-PEG-PLGA) in synergy with a CD44 monoclonal antibody produced via electrospray technique was effective at inhibiting ovarian cancer cell proliferation compared with cisplatin in free form and PLGA without CD44-conjugated NPs (390).